{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:06:34Z","timestamp":1780596394999,"version":"3.54.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003010","name":"Ege University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003010","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Therapeutic resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in the clinical management of chronic myeloid leukemia (CML). The transcription factor STAT5A, a principal downstream effector of BCR::ABL1, has emerged as a key transcriptional regulator implicated in the development of TKI resistance.\u00a0This study aims to functionally validate the role of STAT5A in TKI-resistant CML by employing CRISPR\/Cas9-mediated gene knockout and assessing the downstream molecular and phenotypic alterations. We hypothesized that selective disruption of STAT5A would restore apoptotic sensitivity and TKI responsiveness in resistant CML models. Additionally, we sought to integrate bioinformatic transcriptional network analyses to confirm whether STAT5A directly regulates the genes modulated by its deletion, thus reinforcing its mechanistic relevance as a therapeutic target.\u00a0STAT5A was knocked out using CRISPR\/Cas9 in K562 cells and their TKI-resistant derivatives (K562\/Ima-Res, K562\/Pon-Res). Western blot analysis confirmed effective depletion of STAT5A protein following CRISPR\/Cas9 editing, validating that the observed phenotypic and transcriptional changes were attributable to successful STAT5A knockout. Post-editing, XTT assays were performed to assess cell viability, followed by Annexin V\/PI staining for apoptosis and PI-based flow cytometry for cell cycle analysis. RT-qPCR was used to quantify the expression of key genes involved in the JAK\/STAT pathway (JAK2, STAT3, CISH) and apoptosis\/DNA damage responses (TP53, ATM, CASP3, CASP8). In silico analyses were conducted using TRRUST and Harmonizome\/ChEA3 to confirm whether the genes modulated by STAT5A deletion were direct transcriptional targets. For additional validation, expression matrices from GSE207627 and GSE208314 were reanalyzed to confirm STAT5A-centered pathway alterations in resistant CML datasets.\u00a0STAT5A knockout significantly reduced cell viability and induced apoptosis across all CML cell models, accompanied by G0\/G1 cell cycle arrest. RT-qPCR revealed altered expression of both JAK\/STAT components (JAK2, STAT3, CISH) and apoptosis-related genes (TP53, ATM, CASP3, CASP8). Transcriptional target analysis confirmed that several of these genes\u2014such as CDKN2B, BCL2L1, and CCND1\u2014are direct STAT5A targets, reinforcing the functional consequences of STAT5A loss. Integration of these findings suggests that STAT5A knockout reprograms both intrinsic (CASP3, TP53, ATM) and extrinsic (CASP8, BCL2L1) apoptotic pathways, thereby restoring chemosensitivity. CISH dysregulation further suggested compensatory feedback within the signaling network.\u00a0CRISPR\/Cas9-mediated STAT5A disruption effectively reverses TKI resistance in CML cells by reprogramming apoptotic and proliferative signaling. These findings identify STAT5A as a mechanistically validated and clinically actionable target, supporting its potential for combination strategies with TKIs or STAT5 inhibitors such as pimozide. Integration of transcriptional network analysis supports the mechanistic basis of these effects. STAT5A emerges as a compelling therapeutic target, meriting further investigation in preclinical models and patient-derived samples to evaluate its translational potential. Future validation in patient-derived CD34\u207a CML models may advance STAT5A-based therapeutic design.<\/jats:p>","DOI":"10.1007\/s12032-026-03295-6","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:03:33Z","timestamp":1777107813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting STAT5A via CRISPR\/Cas9 restores TKI sensitivity in resistant chronic myeloid leukemia cells"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-8005","authenticated-orcid":false,"given":"Besne","family":"\u00c7elik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3508-5617","authenticated-orcid":false,"given":"Ya\u011fmur","family":"Kiraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5422-0939","authenticated-orcid":false,"given":"Yaren","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1832-1454","authenticated-orcid":false,"given":"Bur\u00e7in","family":"Tezcanl\u0131 Kaymaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"10","key":"3295_CR1","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/leu.2010.174","volume":"24","author":"J Score","year":"2010","unstructured":"Score J, Calasanz MJ, Ottman O, Pane F, Yeh RF, SobrinhoSim\u00f5es MA, Grand FH. Analysis of genomic breakpoints in p190 and p210 BCR\u2013ABL indicate distinct mechanisms of formation. Leukemia. 2010;24(10):1742\u2013175.","journal-title":"Leukemia"},{"issue":"18","key":"3295_CR2","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.3390\/molecules25184210","volume":"25","author":"F Carofiglio","year":"2020","unstructured":"Carofiglio F, Trisciuzzi D, Gambacorta N, Leonetti F, Stefanachi A, Nicolotti O. Bcr-Abl allosteric inhibitors: where we are and where we are going to. Molecules. 2020;25(18):4210.","journal-title":"Molecules"},{"issue":"24","key":"3295_CR3","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1038\/s41388-02101841-2","volume":"40","author":"P Saraon","year":"2021","unstructured":"Saraon P, Pathmanathan S, Snider J, Lyakisheva A, Wong V, Stagljar I. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. Oncogene. 2021;40(24):4079\u201393. https:\/\/doi.org\/10.1038\/s41388-02101841-2.","journal-title":"Oncogene"},{"issue":"14","key":"3295_CR4","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","volume":"344","author":"JM Goldman","year":"2001","unstructured":"Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1084\u20136. https:\/\/doi.org\/10.1056\/NEJM200104053441409.","journal-title":"N Engl J Med"},{"issue":"5","key":"3295_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/jnci\/djx236","volume":"110","author":"R Mitchell","year":"2018","unstructured":"Mitchell R, Hopcroft LEM, Baquero P, Allan EK, Hewit K, James D, Hamilton G, Mukhopadhyay A, O\u2019Prey J, Hair A, Melo V, Chan J, Ryan E, M K, Maguer-Satta V, Druker BJ, Clark RE, Mitra, Herzyk P, Nicolini FE, Salomoni P, Shanks E, Calabretta B, Holyoake TL, Helgason GV. Targeting BCR-ABL Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. J Natl Cancer Inst. 2018;110(5):467\u201378.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3295_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010215","volume":"14","author":"GP Amarante-Mendes","year":"2022","unstructured":"Amarante-Mendes GP, Rana A, Datoguia TS, Hamerschlak N, Brumatti G. BCR::ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia. Pharmaceutics. 2022;14(1):215. https:\/\/doi.org\/10.3390\/pharmaceutics14010215.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3295_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010240","volume":"12","author":"M Brachet-Botineau","year":"2020","unstructured":"Brachet-Botineau M, Polomski M, Neubauer HA, Juen L, H\u00e9dou D, Viaud-Massuard MC, et al. Pharmacological inhibition of oncogenic STAT3 and STAT5 signaling in hematopoietic cancers. Cancers. 2020;12(1):240. https:\/\/doi.org\/10.3390\/cancers12010240.","journal-title":"Cancers"},{"issue":"20","key":"3295_CR8","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1158\/0008-5472.CAN-18-0195","volume":"78","author":"V Minieri","year":"2018","unstructured":"Minieri V, De Dominici M, Porazzi P, Mariani SA, Spinelli O, Rambaldi A, et al. Targeting STAT5 or STAT5-regulated pathways suppresses leukemogenesis of Ph+ acute lymphoblastic leukemia. Cancer Res. 2018;78(20):5793\u2013807. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0195.","journal-title":"Cancer Res"},{"issue":"10","key":"3295_CR9","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.3109\/10428194.2010.507830","volume":"51","author":"B Kosova","year":"2010","unstructured":"Kosova B, Tezcanli B, Ekiz HA, Cakir Z, Selvi N, Dalmizrak A, Kartal M, Gunduz U, Baran Y. Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. Leuk Lymphoma. 2010;51(10):1895\u2013901. https:\/\/doi.org\/10.3109\/10428194.2010.507830.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"3295_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.32471\/exp-oncology.2312-8852.vol-42-no-2.14533","volume":"42","author":"S Antonenko","year":"2023","unstructured":"Antonenko S, Telegeev G. Inhibition of USP1, a new partner of Bcr-Abl, results in decrease of Bcr-Abl level in K562 cells. Exp Oncol. 2023;42(2):109\u201314. https:\/\/doi.org\/10.32471\/exp-oncology.2312-8852.vol-42-no-2.14533.","journal-title":"Exp Oncol"},{"issue":"11","key":"3295_CR11","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281\u2013308. https:\/\/doi.org\/10.1038\/nprot.2013.143.","journal-title":"Nat Protoc"},{"issue":"11","key":"3295_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.95","volume":"5","author":"X Wang","year":"2016","unstructured":"Wang X, Huang X, Fang X, Zhang Y, Wang W. CRISPR-Cas9 system as a versatile tool for genome engineering in human cells. Molecular therapy Nucleic acids. 2016;5(11):e388. https:\/\/doi.org\/10.1038\/mtna.2016.95.","journal-title":"Molecular therapy. Nucleic acids"},{"key":"3295_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2025.2527464","author":"C Ergun","year":"2025","unstructured":"Ergun C, Kiraz Y, Ayna Duran G. Determination of survival associated genetic biomarkers to discover novel therapeutic targets for acute myeloid leukaemia. J Chemother. 2025. https:\/\/doi.org\/10.1080\/1120009X.2025.2527464.","journal-title":"J Chemother"},{"key":"3295_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2024.115619","volume":"694","author":"B \u00d6zay","year":"2024","unstructured":"\u00d6zay B, T\u00fckel EY, Ayna Duran G, Kiraz Y. Identification of potential inhibitors for drug resistance in acute lymphoblastic leukemia through differentially expressed gene analysis and in silico screening. Anal Biochem. 2024;694:115619. https:\/\/doi.org\/10.1016\/j.ab.2024.115619.","journal-title":"Anal Biochem"},{"issue":"1","key":"3295_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.7240\/jeps.1638390","volume":"37","author":"O Ates","year":"2025","unstructured":"Ates O, Kiraz Y. PSMB8 as a novel target for AML therapy: uncovering synergistic potential with PI3K inhibitors. Int J Adv Eng Pure Sci. 2025;37(1):64\u201372. https:\/\/doi.org\/10.7240\/jeps.1638390.","journal-title":"Int J Adv Eng Pure Sci"},{"issue":"10","key":"3295_CR16","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343\u201356.","journal-title":"Blood"},{"issue":"3","key":"3295_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1634\/stemcells.20-3","volume":"20","author":"A Peled","year":"2002","unstructured":"Peled A, Hardan I, Trakhtenbrot L, Gur E, Magid M, Darash-Yahana M, et al. Immature leukemic CD34\u2009+\u2009CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF 1. Stem cells (Dayton, Ohio). 2002;20(3):259\u201366. https:\/\/doi.org\/10.1634\/stemcells.20-3.","journal-title":"Stem cells (Dayton, Ohio)"},{"issue":"6","key":"3295_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","volume":"112","author":"O Hantschel","year":"2003","unstructured":"Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, et al. A myristoyl\/phosphotyrosine switch regulates c-Abl. Cell. 2003;112(6):845\u201357.","journal-title":"Cell"},{"key":"3295_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cytogfr.2025.05.001","volume":"83","author":"T Shammas","year":"2025","unstructured":"Shammas T, Peiris MN, Meyer AN, Donoghue DJ. BCR-ABL: the molecular mastermind behind chronic myeloid leukemia. Cytokine Growth Factor Rev. 2025;83:45\u201358. https:\/\/doi.org\/10.1016\/j.cytogfr.2025.05.001.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"20","key":"3295_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15205079","volume":"15","author":"I Attili","year":"2023","unstructured":"Attili I, Corvaja C, Spitaleri G, Del Signore E, Trillo Aliaga P, Passaro A, et al. New generations of tyrosine kinase inhibitors in treating NSCLC with oncogene addiction: strengths and limitations. Cancers. 2023;15(20):5079. https:\/\/doi.org\/10.3390\/cancers15205079.","journal-title":"Cancers"},{"issue":"21","key":"3295_CR21","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","volume":"19","author":"T Bowman","year":"2000","unstructured":"Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19(21):2474\u201388. https:\/\/doi.org\/10.1038\/sj.onc.1203527.","journal-title":"Oncogene"},{"issue":"2","key":"3295_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/s1359-6101(99)00011-8","volume":"10","author":"PM Grimley","year":"1999","unstructured":"Grimley PM, Dong F, Rui H. Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev. 1999;10(2):131\u201357. https:\/\/doi.org\/10.1016\/s1359-6101(99)00011-8.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"8","key":"3295_CR23","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1182\/blood-2002-04-1204","volume":"101","author":"M Benekli","year":"2003","unstructured":"Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood. 2003;101(8):2940\u201354. https:\/\/doi.org\/10.1182\/blood-2002-04-1204.","journal-title":"Blood"},{"issue":"3","key":"3295_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/emmm.201000062","volume":"2","author":"A Hoelbl","year":"2010","unstructured":"Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, Hennighausen L, Poli V, Beug H, Moriggl R, Sexl V. EMBO Mol Med. 2010;2(3):98\u2013110. https:\/\/doi.org\/10.1002\/emmm.201000062. Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia.","journal-title":"EMBO Mol Med"},{"issue":"7","key":"3295_CR25","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-12-3955","volume":"73","author":"L Casetti","year":"2013","unstructured":"Casetti L, Martin-Lanner\u00e9e S, Najjar I, Plo I, Aug\u00e9 S, Roy L, Chomel JC, Lauret E, Turhan AG, Dusanter-Fourt I. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem\/progenitor cells. Cancer Res. 2013;73(7):2052\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3955.","journal-title":"Cancer Res"},{"issue":"2","key":"3295_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/s1470-2045(03)00979-3","volume":"4","author":"CB Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003;4(2):75\u201385. https:\/\/doi.org\/10.1016\/s1470-2045(03)00979-3.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3295_CR27","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1021\/ml500165r","volume":"5","author":"AA Cumaraswamy","year":"2014","unstructured":"Cumaraswamy AA, Lewis AM, Geletu M, Todic A, Diaz DB, Cheng XR, et al. Nanomolar-potency small molecule inhibitor of STAT5 protein. ACS Med Chem Lett. 2014;5(11):1202\u20136. https:\/\/doi.org\/10.1021\/ml500165r.","journal-title":"ACS Med Chem Lett"},{"issue":"7569","key":"3295_CR28","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature15248","volume":"525","author":"S Prost","year":"2015","unstructured":"Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, Beressi JP, Verhoeyen E, Raggueneau V, Maneglier B, Castaigne S, Chomienne C, Chr\u00e9tien S, Rousselot P, Leboulch P. Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists. Nature. 2015;525(7569):380\u20133. https:\/\/doi.org\/10.1038\/nature15248.","journal-title":"Nature"},{"issue":"1","key":"3295_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/07391102.2021.2004924","volume":"41","author":"N Gumus","year":"2023","unstructured":"Gumus N, Gunduz C, Tezcanli Kaymaz B. STAT5 inhibitor Pimozide as a probable therapeutic option in overcoming Ponatinib resistance in K562 leukemic cells. J Biomol Struct Dyn. 2023;41(1):186\u201399. https:\/\/doi.org\/10.1080\/07391102.2021.2004924.","journal-title":"J Biomol Struct Dyn"},{"issue":"12","key":"3295_CR30","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","volume":"117","author":"EA Nelson","year":"2011","unstructured":"Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011;117(12):3421\u20139. https:\/\/doi.org\/10.1182\/blood-2009-11-255232.","journal-title":"Blood"},{"issue":"2","key":"3295_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.stem.2014.12.003","volume":"16","author":"C Yu","year":"2016","unstructured":"Yu C, Liu Y, Ma T, Liu K, Xu S, Zhang Y, et al. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell. 2016;16(2):142\u20137. https:\/\/doi.org\/10.1016\/j.stem.2014.12.003.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"3295_CR32","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41587-019-0209-9","volume":"37","author":"X Wu","year":"2019","unstructured":"Wu X, Kriz AJ, Sharp PA. Target specificity of the CRISPR-Cas9 system. Nat Biotechnol. 2019;37(7):789\u201395. https:\/\/doi.org\/10.1038\/s41587-019-0209-9.","journal-title":"Nat Biotechnol"},{"key":"3295_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.omtm.2020.07.002","volume":"18","author":"X Li","year":"2020","unstructured":"Li X, Wang Y, Zhang J. Optimization of CRISPR\/Cas9 delivery and editing efficiency in hematopoietic and leukemia cell lines. Molecular Therapy \u2013 Methods & Clinical Development. 2020;18:614\u201326. https:\/\/doi.org\/10.1016\/j.omtm.2020.07.002.","journal-title":"Molecular Therapy \u2013 Methods & Clinical Development"},{"issue":"10","key":"3295_CR34","doi-asserted-by":"publisher","first-page":"7915","DOI":"10.1007\/s13277-015-3509-9","volume":"36","author":"BT Kaymaz","year":"2015","unstructured":"Kaymaz BT, G\u00fcnel NS, Ceyhan M, \u00c7etinta\u015f VB, \u00d6zel B, Yand\u0131m MK, K\u0131p\u00e7ak S, Aktan \u00c7, G\u00f6kbulut AA, Baran Y, Can BK. Revealing genome wide mRNA and microRNA expression patterns in leukemic cells highlighted hsa miR-2278 as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A. Tumour biology: J Int Soc Oncodevelopmental Biology Med. 2015;36(10):7915\u201327. https:\/\/doi.org\/10.1007\/s13277-015-3509-9.","journal-title":"Tumour biology: J Int Soc Oncodevelopmental Biology Med"},{"key":"3295_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106433","volume":"97","author":"C Sillaber","year":"2020","unstructured":"Sillaber C, Sexl V, Valent P. STAT5 as a therapeutic target in hematologic malignancies. Leuk Res. 2020;97:106433. https:\/\/doi.org\/10.1016\/j.leukres.2020.106433.","journal-title":"Leuk Res"},{"issue":"37","key":"3295_CR36","doi-asserted-by":"publisher","first-page":"40310","DOI":"10.18632\/oncotarget.5821","volume":"6","author":"H Feng","year":"2015","unstructured":"Feng H, Li J, Wang C. Cell cycle arrest and apoptosis induction in K562 cells via imatinib-mediated signaling inhibition. Oncotarget. 2015;6(37):40310\u201320. https:\/\/doi.org\/10.18632\/oncotarget.5821.","journal-title":"Oncotarget"},{"issue":"2","key":"3295_CR37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3892\/or.2020.7869","volume":"45","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wang Y, Yang H, Huang Z, Wang X, Feng W. TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562\/G01 cells by neutralizing the Wnt\/\u03b2-catenin\/TCF7\/ABC transporter signaling axis. Oncol Rep. 2021;45(2):557\u201368. https:\/\/doi.org\/10.3892\/or.2020.7869.","journal-title":"Oncol Rep"},{"issue":"7","key":"3295_CR38","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41375-0180369-5","volume":"33","author":"S Kollmann","year":"2019","unstructured":"Kollmann S, Grundschober E, Maurer B, Warsch W, Grausenburger R, Edlinger L, et al. Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR\/ABL induced leukemia. Leukemia. 2019;33(7):583\u20131597. https:\/\/doi.org\/10.1038\/s41375-0180369-5.","journal-title":"Leukemia"},{"issue":"17","key":"3295_CR39","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1182\/bloodadvances.2022008192","volume":"6","author":"TT Nguyen","year":"2022","unstructured":"Nguyen TT, Li J, Kharas MG. STAT5A\u2013CDK4 signaling axis regulates leukemia cell proliferation and survival. Blood Adv. 2022;6(17):4972\u201385. https:\/\/doi.org\/10.1182\/bloodadvances.2022008192.","journal-title":"Blood Adv"},{"key":"3295_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106643","volume":"109","author":"M Benekli","year":"2021","unstructured":"Benekli M, Uckun FM, Alkan A. Crosstalk between STAT5 and STAT3 signaling in hematologic malignancies. Leuk Res. 2021;109:106643. https:\/\/doi.org\/10.1016\/j.leukres.2021.106643.","journal-title":"Leuk Res"},{"issue":"5","key":"3295_CR41","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/s41418-022-00996-z","volume":"29","author":"AF Thomas","year":"2022","unstructured":"Thomas AF, Kelly GL, Strasser A. Of the many cellular responses activated by TP53, which ones are critical for tumour suppression? Cell Death Differ. 2022;29(5):961\u201371.","journal-title":"Cell Death Differ"},{"issue":"2","key":"3295_CR42","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.leukres.2009.09.026","volume":"34","author":"H de Lavalla","year":"2010","unstructured":"de Lavalla H, Finetti P, Carbuccia N, Khorashad JS, Charbonnier A, Foroni L, et al. A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leuk Res. 2010;34(2):254\u20137. https:\/\/doi.org\/10.1016\/j.leukres.2009.09.026.","journal-title":"Leuk Res"},{"issue":"3","key":"3295_CR43","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/ni.1840","volume":"11","author":"JH Park","year":"2010","unstructured":"Park JH, Adoro S, Guinter T, Erman B, Alag AS, Catalfamo M, Kimura MY, Cui Y, Lucas PJ, Gress RE, Kubo M, Hennighausen L, Feigenbaum L, Singer A. Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells. Nat Immunol. 2010;11(3):257\u201364. https:\/\/doi.org\/10.1038\/ni.1840.","journal-title":"Nat Immunol"},{"issue":"1","key":"3295_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1502-7","volume":"38","author":"Z Nie","year":"2019","unstructured":"Nie Z, Wen F, Xia Q, Zhang P, An H, Luo L, et al. De-regulated STAT5A\/miR-202-5p\/USP15\/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to imatinib resistance. J Exp Clin Cancer Res. 2019;38(1):214. https:\/\/doi.org\/10.1186\/s13046-019-1502-7.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"3295_CR45","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1182\/bloodadvances.2022009734","volume":"7","author":"S Kollmann","year":"2023","unstructured":"Kollmann S, Grundschober E, Maurer B, Warsch W, Stoiber D, Sexl V. Dual targeting of STAT5 and PI3K pathways synergistically overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukemia models. Blood Adv. 2023;7(4):876\u201389. https:\/\/doi.org\/10.1182\/bloodadvances.2022009734.","journal-title":"Blood Adv"},{"issue":"1","key":"3295_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3233\/CBM140434","volume":"15","author":"D Sonkin","year":"2015","unstructured":"Sonkin D, Palmer M, Rong X, Horrigan K, Regnier CH, Fanton C, Holash J, Pinzon-Ortiz M, Squires M, Sirulnik A, Radimerski T, Schlegel R, Morrissey M, Cao ZA. The identification and characterization of a STAT5 gene signature in hematologic malignancies. Cancer Biomark. 2015;15(1):79\u201387. https:\/\/doi.org\/10.3233\/CBM140434.","journal-title":"Cancer Biomark"},{"issue":"11","key":"3295_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111726","volume":"11","author":"B Maurer","year":"2019","unstructured":"Maurer B, Kollmann S, Pickem J, Hoelbl-Kovacic A, Sexl V. STAT5A and STAT5B\u2014twins with different personalities in hematopoiesis and leukemia. Cancers. 2019;11(11):1726. https:\/\/doi.org\/10.3390\/cancers11111726.","journal-title":"Cancers"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03295-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03295-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03295-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:48:29Z","timestamp":1780300109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03295-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["3295"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03295-6","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}